GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » Shiller PE Ratio

Oramed Pharmaceuticals (XTAE:ORMP) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Oramed Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Shiller PE Ratio Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oramed Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oramed Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Oramed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Shiller PE Ratio falls into.



Oramed Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oramed Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Oramed Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.146/131.7762*131.7762
=0.146

Current CPI (Mar. 2024) = 131.7762.

Oramed Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201405 -0.659 100.373 -0.865
201408 -0.622 100.352 -0.817
201411 -0.695 99.635 -0.919
201502 -0.549 99.032 -0.731
201505 -0.549 100.333 -0.721
201508 -0.695 100.548 -0.911
201511 -0.768 100.135 -1.011
201602 -0.512 100.040 -0.674
201605 -0.549 101.355 -0.714
201608 -1.354 101.617 -1.756
201611 -0.732 101.829 -0.947
201702 -0.878 102.779 -1.126
201705 -0.549 103.256 -0.701
201708 -0.732 103.587 -0.931
201711 -0.659 104.072 -0.834
201802 -0.732 105.052 -0.918
201805 -1.098 106.148 -1.363
201808 -0.659 106.383 -0.816
201811 -0.915 106.338 -1.134
201902 -0.768 106.649 -0.949
201905 -0.841 108.048 -1.026
201908 -0.476 108.245 -0.579
201911 -0.549 108.519 -0.667
202002 -0.768 109.139 -0.927
202005 -0.366 108.175 -0.446
202008 -0.439 109.662 -0.528
202011 -0.841 109.793 -1.009
202102 -0.622 110.968 -0.739
202105 -0.622 113.576 -0.722
202108 -0.768 115.421 -0.877
202111 -0.805 117.269 -0.905
202203 -0.988 121.301 -1.073
202206 -0.988 125.017 -1.041
202209 -0.659 125.227 -0.693
202212 -0.805 125.222 -0.847
202303 -0.293 127.348 -0.303
202306 -0.110 128.729 -0.113
202309 -0.293 129.860 -0.297
202312 1.207 129.419 1.229
202403 0.146 131.776 0.146

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals  (XTAE:ORMP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oramed Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Comparable Companies
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.